A meta-analysis of the antiviral activity of the HBV-specific immunotherapeutic TG1050 confirms its value over a wide range of HBsAg levels in a persistent HBV pre-clinical model

Pre-clinical models mimicking persistent hepatitis B virus (HBV) expression are seldom, do not capture all features of a human chronic infection and due to their complexity, are subject to variability. We report a meta-analysis of seven experiments performed with TG1050, an HBV-targeted immunotherap...

Full description

Bibliographic Details
Main Authors: Roland Kratzer, Benoît Sansas, Karine Lélu, Alexei Evlachev, Doris Schmitt, Nathalie Silvestre, Geneviève Inchauspé, Perrine Martin
Format: Article
Language:English
Published: Taylor & Francis Group 2018-06-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Online Access:http://dx.doi.org/10.1080/21645515.2018.1433970